Mr. Paul Tulley

Mr Paul Tulley is a renowned Consultant Plastic, Reconstructive and Cosmetic Surgeon specialising in facial rejuvenation, rhinoplasty, cosmetic breast surgery, liposuction and body contouring procedures. Mr Tulley has a special interest in cosmetic surgery, breast reconstruction and surgery for facial palsy (facial reanimation) where he prides himself on his excellent patient outcomes and clinical results.

Graduating from Charing Cross and Westminster Medical School, London in 1993, Mr Tulley completed his early general surgical training at Charing Cross and University College Hospitals, becoming a fellow of the Royal College of Surgeons in 1997. He then commenced his plastic surgical training at Mount Vernon Hospital and subsequently completed specialist registrar training in plastic surgery at a number of teaching hospitals on the Pan-Thames Plastic Surgery programme. Mr Tulley joined the GMC specialist register for plastic surgery in 2007.

Mr Tulley has been recognised for his esteemed work and research and was awarded an MD by the University of London in 2001 for his research using gene therapy for the treatment of malignant melanoma.

International experience including fellowships in Taipei, Taiwan and Toronto and additional cosmetic surgery experience in the USA and the UK has exposed Mr Tulley to a broad range of cases. Training and working with some of the world’s leading aesthetic surgeons has enhanced Mr Tulley’s extensive skill set, making him one of the UK’s most accomplished cosmetic surgeons.

Mr. Paul Tulley Publications(6)

A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma.

Ramsden AJ, Grover R, Chana J, Tulley P, Sanders R, Wilson GD.

J Plast Reconstr Aesthet Surg. 2007;60(6):626-30

The relation between c-myc expression and interferon sensitivity in uveal melanoma.

Tulley PN, Neale M, Jackson D, Chana JS, Grover R, Cree I, Grobbelaar AO, Wilson GD.

Br J Ophthalmol. 2004 Dec;88(12):1563-7.

The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma.

Chana JS, Grover R, Tulley P, Lohrer H, Sanders R, Grobbelaar AO, Wilson GD.

Br J Plast Surg. 2002 Dec;55(8):623-7.

Sentinel lymph node biopsy for malignant melanoma.

Tulley P, Butler PE.